Study identifies perception gap in incidence, impact of CINV/RINV
the ONA take:
There is a perpetual gap between healthcare professionals and patient perceptions of incidence and impact on patients' daily life of chemotherapy- and radiotherapy-induced nausea and vomiting (CINV/RINV), according to findings presented at the joint Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) 2015 Annual Meeting on Supportive Care in Cancer in Copenhagen, Denmark.
Researchers found that oncologists and oncology nurses overestimate the incidence of CINV/RINV, but underestimate the effect that CINV/RINV has on patients' daily lives. Moreover, data showed that 28% of patients believe oncologists underestimate the impact of CINV/RINV on patients' daily lives.
Results also showed that physicians and nurses believe 60% of patients are fully compliant with physicians' and/or nurses guidelines for self-administration of anti-emetic medications; however, only 38% reported full compliance. Patients reported reluctance to increase pill burden and concern that swallowing would cause nausea/vomiting as reasons for non-compliance.
The findings suggest that the gap between physician and patient perceptions may result in inadequate management of patients' CINV/RINV.
There is a perpetual gap between healthcare professionals and patient perceptions of incidence and impact on patients' daily life of CINV/RINV.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|